Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices
Clinical Kidney Journal · 04.01.2024 · 17 (1)
DOI: 10.1093/ckj/sfad290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 29.11.2023. Verfasst von Maria Fusaro und 24 weiteren Autor:innen. Beteiligte Einrichtung: National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic kidney disease mineral bone disorder (CKD-MBD) is a condition characterized by alterations of calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23) metabolism that in turn promote bone disorders, vascular calcifications, and increase cardiovascular (CV) risk. Nephrologists’ awareness of diagnostic, prognostic, and therapeutic tools to manage CKD-MBD plays a primary role in adequately preventing and managing this condition in clinical practice.
Methods
A national survey (composed of 15 closed questions) was launched to inquire about the use of bone biomarkers in the management of CKD-MBD patients by nephrologists and to gain knowledge about the implementation of guideline recommendations in clinical practice.
Results
One hundred and six Italian nephrologists participated in the survey for an overall response rate of about 10%. Nephrologists indicated that the laboratories of their hospitals were able to satisfy request of ionized calcium levels, 105 (99.1%) of both PTH and alkaline phosphatase (ALP), 100 (94.3%) of 25(OH)D, and 61 (57.5%) of 1.25(OH)2D; while most laboratories did not support the requests of biomarkers such as FGF-23 (intact: 88.7% and c-terminal: 93.4%), Klotho (95.3%; soluble form: 97.2%), tartrate-resistant acid phosphatase 5b (TRAP-5b) (92.5%), C-terminal telopeptide (CTX) (71.7%), and pro-collagen type 1 N-terminal pro-peptide (P1NP) (88.7%). As interesting data regarding Italian nephrologists’ behavior to start treatment of secondary hyperparathyroidism (sHPT), the majority of clinicians used KDOQI guidelines (n = 55, 51.9%). In contrast, only 40 nephrologists (37.7%) relied on KDIGO guidelines, which recommended referring to values of PTH between two and nine times the upper limit of the normal range.
Conclusion
Results point out a marked heterogeneity in the management of CKD-MBD by clinicians as well as a suboptimal implementation of guidelines in Italian clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy.
- Department of Medicine, University of Padova, Padova, Italy.
- Nephrology, Dialysis and Renal Transplant Unit, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università di Milano, Milano, Italy.
- Post-Graduate School of Specialization in Nephrology, University of Milano, Milano, Italy.
- Division of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, Italy.
ORCID-Profile: Maria Fusaro, Maurizio Gallieni, Laura Cosmai, Thomas Nickolas, Serge Ferrari, Mario Plebani, Mario Cozzolino, Piergiorgio Messa
Zitieren
APA
Fusaro, M., Barbuto, S., Gallieni, M., Cossettini, A., Re Sartò, G. V., Cosmai, L., Cianciolo, G., La Manna, G., Nickolas, T., Ferrari, S., Bover, J., Haarhaus, M., Marino, C., Mereu, M. C., Ravera, M., Plebani, M., Zaninotto, M., Cozzolino, M., Bianchi, S., …, & Tripepi, G. (2024). Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices. Clinical Kidney Journal, 17(1). https://doi.org/10.1093/ckj/sfad290
Vancouver
Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sartò GV, Cosmai L, et al. Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices. Clinical Kidney Journal. 2024;17(1). doi:10.1093/ckj/sfad290
BibTeX
@article{Fusaro2024,
author = {Fusaro, Maria and Barbuto, Simona and Gallieni, Maurizio and Cossettini, Althea and Re Sartò, Giulia Vanessa and Cosmai, Laura and Cianciolo, Giuseppe and La Manna, Gaetano and Nickolas, Thomas and Ferrari, Serge and Bover, Jordi and Haarhaus, Mathias and Marino, Carmela and Mereu, Maria Cristina and Ravera, Maura and Plebani, Mario and Zaninotto, Martina and Cozzolino, Mario and Bianchi, Stefano and Messa, Piergiorgio and Gregorini, Mariacristina and Gasperoni, Lorenzo and Agosto, Caterina and Aghi, Andrea and Tripepi, Giovanni},
title = {Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {1},
doi = {10.1093/ckj/sfad290}
}
EUVIMED